EGFR and neoplasm: Briefly, a depletion of CD45(+) leukocytes was carried out by adding an anti-CD45 antibody to exclude nonspecific labeling of the probe in infiltrating immune cells, followed by the addition of HX103 and EGFR antibody to obtain the percent of HX103 labeling in EGFR-positive tumor cells.